Search research articles
Contact Us
Filters
Showing results (121-130 of 185) with videos related to
Page
of 19
Sort By:
Molecular Cancer Therapeutics
|
February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
George D Demetri, Jason J Luke, Antoine Hollebecque, et al.
Journal for Immunotherapy of Cancer
|
June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
Journal for Immunotherapy of Cancer
|
March 8, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Nikhil I Khushalani, Patrick A Ott, Robert L Ferris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Daniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Cell Reports. Medicine
|
December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
Alexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.
Clinical and Translational Science
|
August 10, 2020
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)
John Powderly, Alexander Spira, Shunsuke Kondo, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma
Lilit Karapetyan, Anthony R Cillo, Shuaichao Wang, et al.
Clinical Epigenetics
|
July 30, 2015
Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas
Jonathan J Lee, Lynette M Sholl, Neal I Lindeman, et al.
Page
of 19
Search research articles
Search
Showing results (121-130 of 185) with videos related to
Sort By:
Page
of 19
Molecular Cancer Therapeutics
|
February 8, 2020
Genomic Profiling of Metastatic Uveal Melanoma and Clinical Results of a Phase I Study of the Protein Kinase C Inhibitor AEB071
Sophie Piperno-Neumann, James Larkin, Richard D Carvajal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
George D Demetri, Jason J Luke, Antoine Hollebecque, et al.
Journal for Immunotherapy of Cancer
|
June 6, 2024
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
Joseph J Sacco, Richard D Carvajal, Marcus O Butler, et al.
Journal for Immunotherapy of Cancer
|
March 8, 2024
Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors
Nikhil I Khushalani, Patrick A Ott, Robert L Ferris, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 25, 2022
Combination of the STING Agonist MIW815 (ADU-S100) and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-Label, Multicenter, Phase Ib Study
Funda Meric-Bernstam, Randy F Sweis, Stefan Kasper, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 4, 2021
Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma
Daniel J Olson, Zeynep Eroglu, Bruce Brockstein, et al.
Cell Reports. Medicine
|
December 30, 2020
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule
Alexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, et al.
Clinical and Translational Science
|
August 10, 2020
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)
John Powderly, Alexander Spira, Shunsuke Kondo, et al.
Medrxiv : the Preprint Server for Health Sciences
|
November 24, 2025
Lead-in therapy targeting PD1 and/or LAG3 imposes distinct immune phenotypes in first-line treatment of metastatic melanoma
Lilit Karapetyan, Anthony R Cillo, Shuaichao Wang, et al.
Clinical Epigenetics
|
July 30, 2015
Targeted next-generation sequencing reveals high frequency of mutations in epigenetic regulators across treatment-naïve patient melanomas
Jonathan J Lee, Lynette M Sholl, Neal I Lindeman, et al.
Page
of 19